Mobile

13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkin...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-008712-98

13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate the anti-dyskinetic efficacy, as measured by change from baseline to endpoint at week 12 in the modified AIMS (Abnormal Involuntary Movement Scale) total score, of five fixed doses of AFQ056 versus placebo in patients with moderate to severe PD-LID To estimate the dose-response relationship among five fixed doses of AFQ056 and placebo after 12 weeks of treatment, as measured by the changes from baseline in modified AIMS total score.

Critère d'inclusion

  • moderate to severe levodopa induced dyskinesias in patients with Parkinson's disease

Liens